Interleukin-17A: A unique pathway in immune-mediated diseases: Psoriasis, psoriatic arthritis and rheumatoid arthritis

Immunology

Volumn 141, Issue 2, 2014, Pages 133-142

  Kirkham, Bruce W ^a   Kavanaugh, Arthur ^b   Reich, Kristian ^c  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c DERMATOLOGIKUM HAMBURG   (Germany)

Author keywords

Biological therapy; Interleukin 17A; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis

Indexed keywords

BRODALUMAB; CHEMOKINE; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; IXEKIZUMAB; POLYPEPTIDE ANTIBIOTIC AGENT; SECUKINUMAB;

CD8+ T LYMPHOCYTE; CELL TYPE; CLINICAL FEATURE; DOWN REGULATION; FIBROBLAST; GAMMA DELTA T LYMPHOCYTE; HUMAN; KERATINOCYTE; MAST CELL; MICROENVIRONMENT; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; TARGET CELL; TH17 CELL;

BIOLOGICAL THERAPY; INTERLEUKIN-17A; PSORIASIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS;

ANIMALS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; HUMANS; INTERLEUKIN-17; PSORIASIS; RECEPTORS, INTERLEUKIN-17; SIGNAL TRANSDUCTION;

EID: 84891898217     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12142     Document Type: Review

References (76)

1. + effector T cells develop a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005; 6:1123-32.
2. Park H, Li Z, Yang XO et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005; 6:1133-41.
3. Langrish CL, Chen Y, Blumenschein WM et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005; 201:233-40.
4. Lubberts E, Joosten LAB, Oppers B et al. IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. J Immunol 2001; 167:1004-13.
5. Nakae S, Nambu A, Sudo K, Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 2003; 171:6173-7.
6. Lubberts E, Koenders MI, Oppers-Walgreen B, van den Bersselaar L, Coenen-de Roo CJJ, Joosten LAB, van den Berg WB. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 2004; 50:650-9.
7. Teunissen MB, Koomen CW, de Waal Malefyt R, Wierenga EA, Bos JD. Interleukin-17 and interferon-γ synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol 1998; 111:645-9.
8. Chabaud M, Durand JM, Buchs N, Fossiez F, Page G, Frappart L, Miossec P. Human interleukin-17. A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 1999; 42:963-70.
9. Homey B, Dieu-Nosjen MC, Wiesenborn A et al. Up-regulation of macrophage inflammatory protein-3α/CCL-20 and CC chemokine receptor 6 in psoriasis. J Immunol 2000; 164:6621-32.
10. Raychaudhuri SP. Role of IL-17 in psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol 2013; 44:183-93.
11. Iwakura Y, Ishigame H, Saijo S, Nakae S. Functional specialization of interleukin-17 family members. Immunity 2011; 34:149-62.
12. Gaffen SL. Structure and signaling in the IL-17 receptor family. Nat Rev Immunol 2009; 9:556-67.
13. Cai Y, Shen X, Ding C et al. Pivotal role of dermal IL-17-producing γδ T cells in skin inflammation. Immunity 2011; 35:1-15.
14. Doyle M, Collins E, FitzGerald O, Pennington S. New insight into the functions of the interleukin-17 receptor adaptor protein Act1 in psoriatic arthritis. Arthritis Res Ther 2012; 14:226.
15. Martin D, Towne J, Kricorian G, Klekotka P, Gudjonsson JE, Krueger JG, Russell CB. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol 2013; 133:17-26.
16. Zhu S, Qian Y. IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential. Clin Sci (Lond) 2012; 122:487-511.
17. Hot A, Miossec P. Effects of interleukin (IL)-17A and IL-17F in human rheumatoid arthritis synoviocytes. Ann Rheum Dis 2011; 70:727-32.
18. Sun D, Novotny M, Bulek K, Liu C, Li X, Hamilton T. Treatment with IL-17 prolongs the half-life of chemokine CXCL1 mRNA via the adaptor TRAF5 and the splicing-regulatory factor SF2 (ASF). Nat Immunol 2011; 12:853-60.
19. Bulek K, Liu C, Swaidani S et al. The inducible kinase IKKi is required for IL-17-dependent signaling associated with neutrophilia and pulmonary inflammation. Nat Immunol 2011; 12:844-52.
20. Hot A, Zrioual S, Toh ML, Lenief V, Miossec P. IL-17A- versus IL-17F-induced intracellular signal transduction pathways and modulation by IL-17RA and IL-17RC RNA interference in rheumatoid synoviocytes. Ann Rheum Dis 2011; 70:341-8.
21. Hueber W, Patel DD, Dryja T et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010; 2:52ra72.
22. Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, Braun D, Banerjee S. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012; 366:1190-9.
23. Papp K, Leonardi C, Menter A et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012; 366:1181-9.
24. Fischer-Stabauer M, Boehner A, Eyerich S et al. Differential in situ expression of IL-17 in skin diseases. Eur J Dermatol 2012; 22:781-4.
25. Lin AM, Rubin CJ, Khandpur R et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol 2011; 187:490-500.
26. + T cell trafficking and development by IFN-γ: mechanism and pathological relevance in psoriasis. J Immunol 2008; 181:4733-41.
27. Johansen C, Usher P, Kjellerup R, Lundsgaard D, Iversen L, Kragballe K. Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Br J Dermatol 2009; 160:319-24.
28. Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LC, Haider AS, Bowman EP, Kreuger JG. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008; 128:1207-11.
29. + regulatory T cells involving CTLA4 signaling in a psoriasis-like skin disorder. J Immunol 2010; 184:7257-67.
30. Haider AS, Lowes MA, Suárez-Fariñas M et al. Identification of cellular pathways of "type 1", Th17 T cells, and TNF- and inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomics study of cyclosporine A in psoriasis. J Immunol 2008; 180:1913-20.
31. Zaba LC, Suárez-Fariñas M, Fuentes-Duculan J, Nograles K, Guttman-Yassky E, Cardinale I, Lowes MA, Kreuger JG. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not "immediate-response" TNF genes. J Allergy Clin Immunol 2009; 124:1022-10.e1-395.
32. Nograles KE, Zaba LC, Guttman-Yassky E, Fuentes-Duculan J, Suárez-Fariñas M, Cardinale I. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 2008; 159:1092-1102.
33. Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M, Fouser LA. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006; 203:2271-9.
34. Gutowska-Owsiak D, Schaupp AL, Salimi M, Selvakumar TA, McPherson T, Taylor S, Ogg GS. IL-17 downregulates filaggrin and affects keratinocyte expression of genes associated with cellular adhesion. Exp Dermatol 2012; 21:104-10.
35. Chiricozzi A, Guttman-Yassky E, Suárez-Fariñas M, Nograles KE, Tian S, Cardinale I, Chimenti S, Kreuger JG. Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol 2011; 131:677-87.
36. Papp KA, Langley RG, Sigurgeirsson B et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol 2013; 168:412-21.
37. Rich P, Sigurgeirsson B, Thaçi D et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol 2013; 168:402-11.
38. Krueger JG, Fretzin S, Suárez-Fariñas M et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol 2012; 130:145-54.e9.
39. Mease PJ. Psoriatic arthritis: pharmacotherapy update. Curr Rheumatol Rep 2010; 12:272-80.
40. Lloyd P, Ryan C, Menter A. Psoriatic arthritis: an update. Arthritis 2012; 2012:176298.
41. Jandus C, Bioley G, Rivals JP, Dudler J, Speiser D, Romero P. Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum 2006; 58:2307-17.
42. Raychaudhuri SP, Raychaudhuri SK, Genovese MC. IL-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem 2012; 359:419-29.
43. Noordenbos T, Yeremenko N, Gofita I, van de Sande M, Tak PP, Canete JD, Baeten D. Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. Arthritis Rheum 2012; 64:99-109.
44. McInnes IB, Sieper J, Braun J et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis 2013. PMID: 23361084.
45. Chang C, Gottleib A, Lizzul P. Management of psoriatic arthritis from the view of the dermatologist. Nat Rev Rheumatol 2011; 7:588-98.
46. Emery P, Baeten D, Sieper J et al. Secukinumab induces higher assessment of SpondyloArthritis international society responses over placebo in patients with moderate-to-severe ankylosing spondylitis: results of 28-week, double blind, randomized, placebo-controlled trial. Dermatol Ther 2012; 2:S47.
47. + γδ T cells, drive arthritic bone destruction in mice and humans. J Immunol 2011; 186:2602-12.
48. Hueber AJ, Asquith DL, Miller AM, Reilly J, Kerr S, Leipe J, Melendez AJ, McInnes IB. Cutting edge: mast cells express IL-17A in rheumatoid arthritis synovium. J Immunol 2010; 184:3336-40.
49. Ziolkowska M, Koc A, Luszczykiewicz G, Ksiezopolska-Pietrzak K, Klimczak E, Chwalinska-Sadowska H, Maslinski W. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporine A-sensitive mechanism. J Immunol 2000; 164:2832-8.
50. Metawi SA, Abbas D, Kamal MM, Ibrahim MK. Serum and synovial fluid levels of interleukin-17 in correlation with disease activity in patients with RA. Clin Rheumatol 2011; 30:1201-7.
51. Suurmond J, Dorjée AL, Boon MR, Knol EF, Huizinga TWJ, Toes REM, Schuerwegh AJM. Mast cells are the main interleukin 17-positive cells in antcitrullinated protein antibody-positive and -negative rheumatoid arthritis and osteoarthritis synovium. Arthritis Res Ther 2011; 13:R150.
52. Kirkham BW, Lassere MN, Edmonds JP, Juhasz KM, Bird PA, Lee CS, Schnier R, Portek IJ. Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). Arthritis Rheum 2006; 54:1122-31.
53. Hwang SY, Kim JY, Kim KW, Park MK, Moon Y, Kim WU, Kim HY. IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-κB- and PI3-kinase/AKT-dependent pathways. Arthritis Res Ther 2004; 6:R120-8.
54. Shahrara S, Pickens SR, Mandelin AM II, Karpus WJ, Huang Q, Kolls JK, Pope RM. IL-17-mediated monocyte migration occurs partially through CC chemokine ligand 2/monocyte chemoattractant protein-1 induction. J Immunol 2010; 184:4479-87.
55. Chabaud M, Garnero P, Dayer JM, Guerne PA, Fossiez F, Miossec P. Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis. Cytokine 2000; 12:1092-9.
56. van Bezooijen RL, van der Wee-Pals L, Papapoulos SE, Löwik CWGM. Interleukin 17 synergizes with tumor necrosis factor α to induce cartilage destruction in vitro. Ann Rheum Dis 2002; 61:870-6.
57. Koenders MI, Joosten LAB, van den Berg WB. Potential new targets in arthritis therapy: interleukin (IL)-17 and its relation to tumor necrosis factor and IL-1 in experimental arthritis. Ann Rheum Dis 2006; 65(Suppl. 3):iii29-33.
58. Sato K, Suematsu A, Okamoto K et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006; 203:2673-82.
59. Adamopoulos IE, Chao CC, Geissler R, Laface D, Blumenschein W, Iwakura IE, McClanahan T, Bowman EP. Interleukin-17A upregulates receptor activator of NF-κB on osteoclast precursors. Arthritis Res Ther 2010; 12:R29.
60. Goldberg M, Nadiv O, Luknar-Gabor N, Agar G, Beer Y, Katz Y. Synergism between tumor necrosis factor α and interleukin-17 to induce IL-23 p19 expression in fibroblast-like synoviocytes. Mol Immunol 2009; 46:1854-9.
61. Gullick NJ, Evans HG, Church LD, Jayaraj DM, Filer A, Kirkham BW, Taams LS. Linking power Doppler ultrasound to the presence of Th17 cells in the rheumatoid arthritis joint. PLoS ONE 2010; 5:e12516.
62. 1 Fc fusion protein. Arthritis Rheum 2002; 46:802-5.
63. Koenders MI, Lubberts E, Oppers-Walgreen B et al. Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. Am J Pathol 2005; 167:141-9.
64. Genovese MC, Durez P, Richards HB et al. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomized, placebo controlled study. Ann Rheum Dis 2013; 72:863-9.
65. Genovese MC, Durez P, Richards HB et al. One year efficacy and safety results of a phase II trial of secukinumab in patients with rheumatoid arthritis. Arthritis Rheum 2011; 63(Suppl. 10):S149-50.
66. Genovese MC, Van den Bosch F, Roberson SA, Bojin S, Biagini IM, Ryan P, Sloan-Lancaster J. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis. A phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum 2010; 62:929-39.
67. Genovese MC, Greenwald MW, Cho CS et al. A phase 2 study of multiple subcutaneous doses of LY2439821, an anti-IL-17 monoclonal antibody, in patients with rheumatoid arthritis in two populations: naïve to biologic therapy or inadequate responders to tumor necrosis factor α inhibitors. Arthritis Rheum 2011; 63(Suppl. 10):S1017.
68. Churchill MA, Flores-Suarez LF, Wallace DJ et al. A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab (AMG 827), a human anti-interleukin 17 receptor (IL-17R) antibody, in rheumatoid arthritis. Arthritis Rheum 2012; 64(Suppl. 10):S555.
69. Pavelka K, Chon Y, Newmark R, Erondu N, Lin SL. A randomized, double-blind, placebo-controlled, multiple-dose study to evaluate the safety, tolerability, and efficacy of brodalumab (AMG 827) in subjects with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Rheum 2012; 64(Suppl. 10):S362.
70. Ruderman E. Overview of safety of non-biologic and biologic DMARDs. Rheumatology 2012; 51:vi37-vi43.
71. Puel A, Cypowyj S, Bustamante J et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 2011; 332:65-8.
72. Puel A, Döffinger R, Natividad A et al. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med 2010; 207:291-7.
73. Kisand K, Bøe Wolff AS, Podkrajsek KT et al. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J Exp Med 2010; 207:299-308.
74. van de Veerdonk FL, Plantinga TS, Hoischen A et al. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N Engl J Med 2011; 365:54-61.
75. Chandesris MO, Melki I, Natividad A et al. Autosomal dominant STAT3 deficiency and hyper-IgE syndrome: molecular, cellular, and clinical features from a French national survey. Medicine (Baltimore) 2012; 91:e1-19.
76. Hueber W, Sands B, Lewitsky S et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomized, double-blind placebo-controlled trial. Gut 2012; 61:1693-700.